Pharmacokinetic changes in drugs during protein-calorie malnutrition: Correlation between drug metabolism and hepatic microsomal cytochrome P450 isozymes

Archives of Pharmacal Research

Volumn 27, Issue 7, 2004, Pages 693-712

  Joo, Hyun Lee ^a   Ok, Kyung Suh ^b   Myung, Gull Lee ^a  

^a Seoul National University   (South Korea)

^b LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

Author keywords

CYP isozymes; Kwashiorkor; Marasmus; PCM; Pharmacokinetics

Indexed keywords

CYTOCHROME P450; DRUG; ISOENZYME;

ANIMAL; ENZYMOLOGY; HUMAN; LIVER MICROSOME; METABOLISM; PHARMACOKINETICS; PROTEIN CALORIE MALNUTRITION; REVIEW;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PROTEIN-ENERGY MALNUTRITION;

EID: 16644377167     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02980136     Document Type: Review

References (193)

1. Adelusi, S. A. and Salako, L. A., The effect of protein-energy malnutrition on the absorption, distribution and elimination of chloroquine in the rat. Gen. Pharmacol., 13, 505-509 (1982).
2. Ahn, C. Y., Kim, E. J., Kwon, J. W., Chung, S. J., Kim, S. G., Shim, C.-K., and Lee, M. G., Effects of cysteine on the pharmacokinetics of intravenous clarithromycin in rats with protein-calorie malnutrition. Life Sci., 73, 1783-1794 (2003).
3. Akinyinka, O. O., Sowunmi, A., Honeywell, R., and Renwick, A. G., The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. Eur. J. Clin. Pharmacol., 56, 153-158 (2000).
4. Anderson, K. E., Schneider, J., Pantuck, E. J., Pantuck, C. B., Mudge, G. H., Welch, R. M., Conney, A. H., and Kappas, A., Acetaminophen metabolism in subjects fed charcoal-broiled beef. Clin. Pharmacol. Ther., 34, 369-374 (1983).
5. Arunkumar, S. R. and Krishnaswamy, K., Metabolism of sulphadiazine in malnutrition. Br. J. Clin. Pharmacol., 7, 69-73 (1979).
6. Asano, T., Inoue, T., and Kurono, M., Disposition of azosemide. I. Distribution, metabolism and excretion following intravenous administration to rats. Yakugaku Zasshi, 104, 1181-1190 (1984).
7. Ashton, M., Bolme, P., Alemayehu, E., Eriksson, M., and Paalzow, L., Decreased chloramphenicol clearance in malnourished Ethiopian children. Eur. J. Clin. Pharmacol., 45, 181-186 (1993a).
8. Ashton, M., Bolme, P., Zerihun, G., Holmberg, K., and Paalzow, L. K., Disposition of salicylic acid in malnourished Ethiopian children after single oral dose. Clin. Pharmacokinet., 25, 483-494 (1993b).
9. Bae, S. K., Lee, A. K., Kwon, J. W., Chung, S. J., Kim, S. G., Shim, C.-K., and Lee, M. G., Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. J. Pharm. Sci., in press (2004a).
10. Bae, S. K., Chung, W.-S., Kim, E. J., Rhee, J. K., Kwon, J. W., Kim, W. B., and Lee, M. G., Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: Intestinal first-pass effect. Antimicrob. Agents. Chemother., 48, 659-662 (2004b).
11. Bae, S. K., Lee, S. J., Kwon, J. W., Kim, W. B., and Lee, M. G., Effects of protein-calorie malnutrition on the pharmacokinetics of DA-7867, a new oxazolidinone, in rats. J. Pharm. Sci., in press (2004c).
12. Bano, G., Raina, R. K., and Sharma, D. B., Pharmacokinetics of carbamazepine in protein-energy malnutrition. Pharmacology, 32, 232-236 (1986).
13. Beermann, B. and Grind, M., Clinical pharmacokinetics of some newer diuretics. Clin. Pharmacokinet., 13, 254-266 (1987).
14. Bergan, T., Ortengren, B., and Westerlund, D., Clinical pharmacokinetics of cotrimazine. Clin. Pharmacokinet., 11, 372-386 (1986).
15. Bistrian, B. R., Blackburn, G. L., Hallowell, E., and Heddle, R., Protein status of general surgical patients. J. Am. Med. Assoc., 230, 858-860 (1974).
16. Bistrian, B. R., Blackburn, G. L., Vitale, J., Cochran, D., and Naylor, J., Prevalence of malnutrition in general medical patients. J. Am. Med. Assoc., 235, 1567-1570 (1976).
17. Bolme, P., Eriksson, M., Habte, D., and Paalzow, L., Pharmacokinetics of streptomycin in Ethiopian children with tuberculosis and of different nutritional status. Eur. J. Clin. Pharmacol., 33, 647-649 (1988).
18. Bolme, P., Eriksson, M., Paalzow, L., Stintzing, G., Zerihun, G., and Woldemariam, T., Malnutrition and pharmacokinetics of penicillin in Ethiopian children. Pharmacol. Toxicol., 76, 259-262 (1995).
19. Brater, D. C., Day, B., Anderson, S., and Seiwell, R., Azosemide kinetics and dynamics. Clin. Pharmacol. Ther., 34, 454-458 (1983).
20. Bravo, I. G., Bravo, M. E., Plate, G., Merlez, J., and Arancibia, A., The pharmacokinetics of cotrimoxazole sulphonamide in malnourished (marasmic) infants. Pediatr. Pharmacol. (New York), 4, 167-176 (1984).
21. Bredberg, E. and Paalzow, L. K., Altered pharmacokinetics and dynamics of apomorphine in the malnourished rat: Modeling of the composed relationship between concentration and heart-rate response. Pharm. Res., 7, 318-324 (1990).
22. Bu, S. C., Kim, Y. G., Kim, S. H., and Lee, M. G., Effects of enzyme inducers and inhibitor on the pharmacokinetics of intravenous 2-(allylthio)pyrazine, a new chemoprotective agent, in rats. Biopharm. Drug Dispos., 21, 157-164 (2000).
23. Buchanan, N., Drug kinetics in protein-energy malnutrition. S. Afr. Med. J., 53, 327-330 (1978).
24. Buchanan, N., Davis, M. D., and Eyberg, C., Gentamicin pharmacokinetics in kwashiorkor. Br. J. Clin. Pharmacol., 8, 451-453 (1979a).
25. Buchanan, N., Eyberg, C., and Davis, M. D., Antipyrine pharmacokinetics and D-glucaric excretion in kwashiorkor. Am. J. Clin. Nutr., 32, 2439-2442 (1979b).
26. Buchanan, N., Eyberg, C., and Davis, M. D., Isoniazid pharmacokinetics in kwashiorkor. S. Afr. Med. J., 56, 299-300 (1979c).
27. Buchanan, N., Robinson, R., Koornhof, H. J., and Eyberg, C., Penicillin pharmacokinetics in kwashiorkor. Am. J. Clin. Nutr., 32, 2233-2236 (1979d).
28. Butler, M. A., Iwasaki, M., Guengerich, F. P., and Kadlubar, F. F., Human cytochrome P-450PA (P-450IA2), the phenacetin Odeethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. U.S.A., 86, 7696-7700 (1989).
29. Chambers, H. F., Chapter 47. Protein synthesis, inhibitors and miscellaneous antibacterial agents, In Goodman & Gilman, The Pharmacological basis of therapeutics. Hardman, J. G., Limbird, L. L., and Gilman, A. G., 10th (ed). Mc Graw-Hill, Medical Publishing Division, New York. p. 1242 (2001).
30. Charland, S. L., Bartlett, D., and Torosian, M. H., Effect of protein-calorie malnutrition on methotrexate pharmacokinetics. J. Parenter. Enteral. Nutr., 18, 45-49 (1994).
31. Chen, W., Koenigs, L. L., Thompson, S. J., Peter, R. M., Rettie, A. E., Trager, W. F., and Nelson, S. D., Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. Chem. Res. Toxicol., 11, 295-301 (1998).
32. Cho, M. K., Kim, Y. G., Lee, M. G., and Kim, S. G., Suppression of rat hepatic cytochrome P450s by protein-calorie malnutrition: Complete or partial restoration by cysteine or methionine supplementation. Arch. Biochem. Biophys., 372, 150-158 (1999).
33. Cho, M. K., Kim, Y. G., Lee, M. G., and Kim, S. G., The effect of cysteine on the altered expression of class α and μ glutathione S-transferase genes in the rat liver during proteincalorie malnutrition. Biochem. Biohys. Acta., 1502, 235-245 (2000).
34. Cho, M. K., Kim, Y. G., Lee, M. G., and Kim, S. G., Prevention of c-Jun/activator protein-1 activation and microsomal epoxide hydrolase induction in the rat liver by cysteine during proteincalorie malnutrition. Biochem. Pharmacol., 61, 15-24 (2001).
35. Choi, Y. M., Kim, S. H., and Lee, M. G., Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and pharmacodynamics of furosemide in rats. J. Pharm. Sci., 80, 638-642 (1991a).
36. Choi, Y. M., Lee, S. H., Jang, S. H., and Lee, M. G., Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and the pharmacodynamics of bumetanide in rats. Biopharm. Drug Dispos., 12, 311-324 (1991b).
37. Chung, H. C., Sung, S. H., Kim, J. S., Kim, Y. C., and Kim, S. G., Lack of cytochrome P450 2E1 (CYP2E1) induction in the rat liver by starvation without coprophagy. Drug Metab. Dispos., 29, 213-216 (2001).
38. Conney, A. H. and Burns, J. J., Physiological disposition and metabolic fate of chlorzoxazone (Paraflex) in man. J. Pharmacol. Exp. Ther., 128, 340-343 (1960).
39. Cook, J. A., Smith, D. E., Cornish, L. A., Tankanow, R. M., Nicklas, J. M., and Hyneck, M. L., Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure. Clin. Pharmacol. Ther., 44, 487-500 (1988).
40. Correia, M. A. and Appendix, B., Rat and human liver cytochromes P450. Substrate and inhibitor specificities and functional markers, In cytochrome P450. Structure, Mechanism, and Biochemistry (2nd edn), Oritz de Montellano PR (ed.) Pleum Press; New York and London, 607-630 (1995).
41. Crom, W. R. and Evans, W. E., Chapter 29. Methotrexate, in Applied pharmacokinetics. Principles of therapeutic drug monitoring. 2nd ed. Evans, W. E., Schontag, J. J., Jusko, W. J., (ed). Applied therapeutics, Vancouver, WA, pp. 29-1-29-42 (1992).
42. Cusack, B. J., Young, S. P., Loseke, V. L., Hurty, M. R., Beals, L., and Olson, R. D., Effect of a low-protein diet on doxorubicin pharmacokinetics in the rabbit. Cancer Chemother. Pharmacol., 30, 145-148 (1992).
43. Cuttle, L., Munns, A. J., Hogg, N. A., Scott, J. R., Hooper, W. D., Dickinson, R. G., and Gillam, E. M., Phenytoin metabolism by human cytochrome P450: Involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation. Drug Metab. Dispos., 28, 945-950 (2000).
44. Davis, L. E., Lenkinski, R. E., Shinkwin, M. A., Kressel, H. Y., and Daly, J. M., The effect of dietary protein depletion on hepatic 5-fluorouracil metabolism. Cancer, 72, 3715-3722 (1993).
45. Denke, M. and Wilson, J. D., Protein and energy malnutrition. In: Principles of internal medicine Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, (ed). 14th ed. New York: McGraw-Hill. 452-454 (1998).
46. Dodson, W. E. and Rust, R. S., Phenobarbital: Absorption, distribution, and excretion. In: Antiepileptic drugs. Levy RH, Mattson RH, Meldrum BS, (ed). 4th ed. New York: Raven Press, pp. 379-387 (1995).
47. Eriksson, M., Paalzow, L., Bolme, P., and Mariam, T. W., Chloramphenicol pharmacokinetics in Ethiopian children of differing nutritional status. Eur. J. Clin. Pharmacol., 24, 819-823 (1983).
48. Forman, W. B., Davidson, E. D., and Webster, L. T. Jr., Enzymatic conversion of salicylate to salicylurate. Mol. Pharmacol., 7, 247-259 (1971).
49. Friedel, H. A. and Buckley, M. M., Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs, 41, 81-103 (1991).
50. Galinsky, R. E. and Levy, G., Dose- and time-dependent elimination of acetaminophen in rats: Pharmacokinetic implications of cosubstrate depletion. J. Pharmacol. Exp. Ther., 219, 14-20 (1981).
51. Giancarlo, G. M., Venkatakrishnan, K., Granda, B. W., von Moltke, L. L., and Greenblatt, D. J., Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: Inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur. J. Clin. Pharmacol., 57, 31-36 (2001).
52. Greenblatt, D. J., Clinical pharmacokinetics of oxazepam and lorazepam. Clin. Pharmacokinet., 6, 89-105 (1981).
53. 14C]-lorazepam. Clin. Pharmacol. Ther., 20, 329-341 (1976).
54. Greven, J. and Heidenreich, O., Renal actions of azosemide. 2. Micropuncture investigations in rats. Arzneim.-Forsch./Drug Res., 31, 350-353 (1981).
55. Halladay, S. C., Sipes, I. G., and Carter, D. E., Diuretic effect and metabolism of bumetanide in man. Clin. Pharmacol. Ther., 22, 179-187 (1977).
56. Halpert, J. R., Multiplicity of steroid-inducible cytochrome P-450 in rat liver microsomes. Arch. Biochem. Biophys., 263, 59-68 (1988).
57. Han, K. S. and Lee, M. G., Effect of a new chemoprotective agent, 2-(allylthio)pyrazine, on the pharmacokinetics of intravenous theophylline in rats. Int. J. Pharm., 184, 237-242 (1999).
58. Hargreaves, J. A., Howald, W. N., Racha, J. K., and Levy, R. H., Identification of enzymes responsible for the metabolism of phenobarbital. In: ISSX Proceedings; 7th North American ISSX Meeting; San Diego. Bethesda, MD: International Society for the Study of Xenobiotics, p. 259 (1996).
59. Hendricks, M. K., Van Der Bijl, P., Parkin, D. P., and Donald, P. R., Pharmacokinetics of amikacin in children with kwashiorkor. Ann. Trop. Paediatr., 15, 295-298 (1995).
60. Heykants, J., Michiels, M., Meuldermans, W., Monbaliu, J., Lavrijsen, K., van Peer, A., Levron, J. C., Woestenborghs, R., and Cauwenberg, G., The pharmacokinetics of itraconazole in humans: An overview, In Recent trends in the discovery, development and evaluation of antifungal agents. Promtling RA (ed). Prous Science Publishers, Barcelona, 223-229 (1987).
61. Heykants, J., van Peer, A., van de Velde, V., van Rooy, P., Meuldermans, W., Lavrijsen, K., Woestenborghs, R., van Cutsem, J., and Cauwenbergh, G., The clinical pharmacokinetics of itraconazole. An overview. Mycoses, 32 (Suppl. 1), 67-87 (1989).
62. Homeida, M., Karrar, Z. A., and Roberts, C. J., Drug metabolism in malnourished children: A study with antipyrine. Arch. Dis. Child., 54, 299-302 (1979).
63. Ingelman-Sundberg, M., Kaur, H., Terelius, Y., Persson, J. O., and Halliwell, B., Hydroxylation of salicylate by microsomal fractions and cytochrome P-450. Lack of production of 2,3-dihydroxybenzoate unless hydroxyl radical formation is permitted. Biochem. J., 276, 753-757 (1991).
64. Janssen Pharmaceutica and Research Foundation, Janssen One-to-One Customer Action Center, Janssen Pharmaceutica Products, LR, April, p. 1 (2001).
65. Janus, K., Antoszek, J., and Suszycki, S., The effect of short-term starvation or water deprivation on caffeine pharmacokinetics in calves. Res. Vet. Sci., 70, 109-113 (2001).
66. Jung, D., Disposition of acetaminophen in protein-calorie malnutrition. J. Pharmacol. Exp. Ther., 232, 178-182 (1985a).
67. Jung, D., Pharmacokinetics of theophylline in protein-calorie malnutrition. Biopharm. Drug Dispos., 6, 291-299 (1985b).
68. Jung, D. and Nanavaty, M., The effects of age and dietary protein restriction on the pharmacokinetics of theophylline in the rat. Pharmacol. Toxicol., 66, 361-366 (1990).
69. Jung, D., Nanavaty, M., and Prasad, P., Disposition of procainamide and N-acetylprocainamide in protein-calorie malnutrition. Drug Metab. Dispos., 13, 359-363 (1985).
70. Jung, D., Lam, H. D., and Chu, M., Absorption and disposition kinetics of chlorothiazide in protein-calorie malnutrition. Biopharm. Drug Dispos., 11, 53-60 (1990).
71. Kapelanski, D. P., Daly, J. M., Copeland, E. M. 3rd., and Dudrick, S. J., Doxorubicin pharmacokinetics - The Effect of protein deprivation. J. Surg. Res., 30, 331-337 (1981).
72. Kawamura, A., Yoshida, Y., Kimura, N., Oda, H., and Kakinuma, A., Phosphorylation/dephosphorylation steps are crucial for the induction of CYP2B1 and CYP2B2 gene expression by phenobarbital. Biochem. Biophys. Res. Commun., 264, 530-536 (1999).
73. Kim, S. H. and Lee, M. G., Influence of protein and calorie malnutrition on the pharmacokinetics and pharmacodynamics of bumetanide in rats. J. Pharm. Sci., 82, 838-843 (1993).
74. Kim, E. J. and Lee, M. G., Pharmacokinetics and pharmacodynamics of intravenous torasemide in mutant nagase analbuminemic rats. Biopharm. Drug Dispos., 24, 27-35 (2003).
75. Kim, S. H., Choi, Y. M., and Lee, M. G., Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J. Pharmacokinet. Biopharm., 21, 1-17 (1993).
76. Kim, Y. G., Yoon, E. J., Yoon, W. H., Shim, H. J., Lee, S. D., Kim, W. B., Yang, J., and Lee, M. G., Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein-calorie malnutrition rats. Biopharm. Drug Dispos., 17, 183-195 (1996).
77. Kim, N. D., Kwak, M. K., and Kim, S. G., Inhibition of cytochrome P450 2E1 expression by 2-(allylthio)pyrazine, a potential chemoprotective agent: Hepatoprotective effects. Biochem. Pharmacol., 53, 261-269 (1997).
78. Kim, Y. G., Cho, M. K., Kwon, J. W., Kim, S. G., and Lee, M.G., Effects of cysteine on the pharmacokinetics of intravenous adriamycin in rats with protein-calorie malnutrition. Res. Commun. Mol. Pathol. Pharmacol., 107, 361-376 (2000).
79. Kim, Y. G., Cho, M. K., Kwon, J. W., Kim, S. G., Chung, S. J., Shim, C.-K., and Lee, M. G., Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. Int. J. Pharm., 229, 45-55 (2001a).
80. Kim, Y. G., Cho, M. K., Kwon, J. W., Kim, S. G., Kim, S. H., and Lee, M. G., Effects of cysteine on the pharmacokinetics and pharmacodynamics of intravenous and oral azosemide in rats with protein-calorie malnutrition. Life Sci., 68, 2329-2345 (2001b).
81. Kim, Y. G., Cho, M. K., Kwon, J. W., Kim, S. G., Chung, S. J., Shim, C.-K., and Lee, M. G. Effects of cysteine on the pharmacokinetics of intravenous chlorzoxazone in rats with protein-calorie malnutrition. Biopharm. Drug Dispos., 23, 121-129 (2002).
82. Kim, Y. G., Cho, M. K., Kwon, J. W., Kim, D. H., Kim, S. G., and Lee, M. G., Effects of cysteine on the pharmacokinetics of intravenous 2-(allylthio)pyrazine, a new chemoprotective agent, in rats with protein-calorie malnutrition. Int. J. Pharm., 255, 1-11 (2003a).
83. Kim, E. J., Suh, O. K., and Lee, M. G., Pharmacokinetics of intravenous theophylline in mutant Nagase analbuminemic rats. Life Sci., 72, 1231-1245 (2003b).
84. Knauf, H. and Mutschler, E., Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin. Pharmacokinet., 34, 1-24 (1998).
85. 14C]-bumetanide in the rat and their excretion by rats and dogs. Drug Metab. Dispos., 4, 169-176 (1976).
86. Komatsu, T., Yamazaki, H., Asahi, S., Gillam, E. M., Guengerich, F. P., Nakajima, M., and Yokoi, T., Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: Roles of cytochromes P450 2C9, 2C19, and 3A4. Drug Metab. Dispos., 28, 1361-1368 (2000).
87. Koren, G., Clinical pharmacokinetic significance of the renal tubular secretion of drugs. Clin. Pharmacokinet., 15, 165-179 (1988).
88. Krishnaswamy, K., Drug metabolism and pharmacokinetics in malnutrition. Clin. Pharmacokinet., 3, 216-240 (1978).
89. Krishnaswamy, K., Ushasri, V., and Naidu, N. A., The effect of malnutrition on the pharmacokinetics of phenylbutazone. Clin. Pharmacokinet., 6, 152-159 (1981).
90. Lambert, C., Larochelle, P., and du Souich, P., Effects of phenobarbital and tobacco smoking on furosemide kinetics and dynamics in normal subjects. Clin. Pharmacol. Ther., 34, 170-175 (1983).
91. Lamp, K. C., Freeman, C. D., Klutman, N. E., and Lacy, M. K., Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin. Pharmacokinet., 36, 353-373 (1999).
92. 2 blockers. J. Clin. Pharmacol., 37, 535-540 (1997).
93. Lares-Asseff, I., Cravioto, J., Santiago, P., and Perez-Ortiz, B., Pharmacokinetics of metronidazole in severely malnourished and nutritionally rehabilitated children. Clin. Pharmacol. Ther., 51, 42-50 (1992).
94. Lares-Asseff, I., Cravioto, J., Santiago, P., and Perez-Ortiz, B., A new dosing regimen for metronidazole in malnourished children. Scand. J. Infect. Dis., 25, 115-121 (1993).
95. Lee, S. H., M.S. Thesis, Seoul National University, Seoul, Korea (1991).
96. Lee, S. H. and Lee, M. G., Pharmacokinetics and pharmacodynamics of azosemide after intravenous and oral adminis-tration to rats: Absorption from various GI segments. J. Pharmacokinet. Biopharm., 24, 551-568 (1996).
97. Lee, S. H. and Lee, M. G., Effect of phenobarbital, 3-methylcholanthrene, and chloramphenicol pretreatment on the pharmacokinetics and pharmacodynamics of azosemide in rats. Biopharm. Drug Dispos., 18, 371-386 (1997).
98. Lee, H. J. and Lee, M. G., Effects of dexamethasone on the pharmacokinetics of adriamycin after intravenous administration to rats. Res. Commun. Mol. Pathol. Pharmacol., 105, 87-96 (1999).
99. Lee, W. I., Yoon, W. H., Shin, W. G., Song, I. S., and Lee, M. G., Pharmacokinetics and pharmacodynamics of furosemide after direct administration into the stomach or duodenum. Biopharm. Drug Dispos., 18, 753-767 (1997).
100. Lee, A. K., Kang, K. W., Kim, Y. G., Cho, M. K., Lee, M. G., Shim, C. K., Chung, S. J., and Kim, S. G., Identification of genes enhanced by protein-calorie malnutrition by differential display polymerase chain reaction (expression of fibrinogen B β chain, B cell translocation gene 1 and thyroid hormone responsive protein genes). Mol. Cell. Biochem., 231, 163-171 (2002).
101. Lee, A. K., Ahn, C. Y., Kim, E. J., Kwon, J. W., Chung, S. J., Kim, S. G., Shim, C.-K., and Lee, M. G., Effects of cysteine on the pharmacokinetics of itraconazole in rats with proteincalorie malnutrition. Biopharm. Drug Dispos., 24, 63-70 (2003).
102. Lee, A. K., Lee, J. H., Kwon, J. W., Kim, W. B., Kim, S. G., Kim, S. H., and Lee, M. G., Pharmacokinetics of clarithromycin in rats with acute renal failure induced by uranyl nitrate. Biopharm. Drug Dispos., (2004) (in press).
103. Lelo, A., Miners, J. O., Robson, R. A., and Birkett, D. J., Quantitative assessment of caffeine partial clearances in man. Br. J. Clin. Pharmacol., 22, 183-186 (1986).
104. Lessard, E., Fortin, A., Belanger, P. M., Beaune, P., Hamelin, B. A., and Turgeon, J., Role of CYP2D6 in the N-hydroxylation of procainamide. Pharmacogenetics, 7, 381-390 (1997).
105. Levy, R. H., Thummel, K. E., Trager, W., F., Hansten, P., D., and Eichelbaum, M., Metabolic drug interactions. Lippincott Williams & Wilkins, a Wolters Kluwer Company, Philadelphia, Baltimore, New York, London, Buenos Aires, Hongkong, Sydney, Tokyo (2000).
106. Lewis, D. F. V., Cytochrome P450. Structure, function and mechanism. Bristol: Talyor & Francis (1996a).
107. Lewis, D. F. V., P450 substrate specificity and metabolism. In: Cytochromes P450. Structure, function and mechanism. Bristol: Talyor & Francis, p. 123 (1996b).
108. Lieber, C. S., Cytochrome P-4502E1: Its physiological and pathological role. Physiol. Rev., 77, 517-544 (1997).
109. Locniskar, A. and Greenblatt, D. J., Oxidative versus conjugative biotransformation of temazepam. Biopharm. Drug Dispos., 11, 499-506 (1990).
110. Longo, V., Ingelman-Sundberg, M., Amato, G., Salvetti, A., and Gervasi, P. G., Effect of starvation and chlormethiazole on cytochrome P450s of rat nasal mucosa. Biochem. Pharmacol., 59, 1425-1432 (2000).
111. Lovless, H., Arena, E., Felsted, R. L., and Bachur, N. R., Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res.,38, 593-598 (1978).
112. Lucas, D., Ferrara, R., Gonzalez, E., Bodenez, P., Albores, A., Manno, M., and Berthou, F., Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. Pharmacogenetics, 9, 377-388 (1999).
113. Mehta, S., Kalsi, H. K., Jayaraman, S., and Mathur, V. S., Chloramphenicol metabolism in children with protein-calorie malnutrition. Am. J. Clin. Nutr., 28, 977-981 (1975).
114. Mehta, S., Nain, C. K., Sharma, B., and Mathur, V. S., Metabolism of sulfadiazine in children with protein calorie malnutrition. Pharmacology, 21, 369-374 (1980).
115. Mehta, S., Nain, C. K., Sharma, B., and Mathur, V. S., Disposition of four drugs in malnourished children. Drug Nutr. Interact., 1, 205-211 (1982).
116. Meuldermans, W., Hendrickx, J., van Peer, A., Mostmans, E., Bockx, M., Roelant, D., Woestenborghs, R., Gasparini, R., Lauwers, W., van Cutsem, J., and Heykants, J., Absorption, excretion and metabolism of itracoanzole in volunteers after a single oral dose. Clinical Research Report, R. 51211/33, Janssen Pharmaceutica, Beerse, Belgium (1986).
117. Mihranian, M. H., Wang, Y. M., and Daly, J. M., Effects of nutritional depletion and repletion on plasma methotrexate pharmacokinetics. Cancer, 54, 2268-2271 (1984).
118. Miners, J. O., Attwood, J., and Birkett, D. J., Determinants of acetaminophen metabolism: Effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. Clin. Pharmacol. Ther., 35, 480-486 (1984).
119. Miners, J. O., Rees, D. L. P., Valente, L., Veronese, M. E., and Birkett, D. J., Human hepatic cytochrome P450 2C9 catlayzes the rate-limiting pathway of torasemide metabolism. J. Pharmacol. Exp. Ther., 272, 1076-1081 (1995).
120. Mirghani, R. A., Yasar, U., Zheng, T., Cook, J. M., Gustafsson, L. L., Tybring, G., and Ericsson, O., Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway. Drug Metab. Dispos., 30, 1368-1371 (2002).
121. Mross, K., Maessen, P., van der Vijgh, W. J., Gall, H., Boven, E., and Pinedo, H. M., Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J. Clin. Oncol., 6, 517-526 (1988).
122. Narang, R. K., Mehta, S., and Mathur, V. S., Pharmacokinetic study of antipyrine in malnourished children. Am. J. Clin. Nutr., 30, 1979-1982 (1977).
123. Nehru, B., Mehta, S., Nain, C. K., and Mathur, V. S., Disposition of sulphadiazine in young rhesus monkeys with protein calorie malnutrition. Int. J. Clin. Pharmacol. Ther. Toxicol., 26, 509-512 (1988).
124. Neugebauer, G., Besenfelder, E., and von Mollendorff, E., Pharmacokinetics and metabolism of torasemide in man. Arzneim.-Forsch./Drug Res., 38, 164-166 (1988).
125. Ogilvie, R. I., Clinical pharmacokinetics of theophylline. Clin. Pharmacokinet., 3, 267-293 (1978).
126. Ogiso, T., Iwaki, M., Tanaka, H., Kobayashi, E., Tanino, T., Sawada, A., and Uno, S., Pharmacokinetic drug interactions between ampiroxicam and sulfaphenazole in rats. Bilo. Pharm. Bull., 22, 191-196 (1999).
127. Ortiz de Montellano P. R., Cytochrome P450; Structure, mechanism, and biochemistry, 2nd ed. Plenum Press, New York and London (1995).
128. O'Shea, D., Davis, S. N., Kim, R. B., and Wilkinson, G. R., Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: A putative probe of CYP2E1 activity. Clin. Pharmacol. Ther., 56, 359-367 (1994).
129. Otterness, D. M., Keith, R. A., Kerremans, A. L., and Weinshilboum, R. M., Mouse liver thiol methyltransferase. Assay conditions, biochemical properties, and strain variation. Drug Metab. Dispos., 14, 680-688 (1986).
130. Ouellet, D., Hsu, A., Granneman, G. R., Carlson, G., Cavanaugh, J., Guenther, H., and Leonard, J. M., Pharmacokinetic interaction between ritonavir and clarithromycin. Clin. Pharmacol. Ther., 64, 355-362 (1998).
131. Pantuck, E. J., Pantuck, C. B., Weissman, C., Gil, K. M., and Askanazi, J., Stimulation of oxidative drug metabolism by parenteral refeeding of nutritionally depleted patients. Gastroenterology, 89, 241-245 (1985).
132. Patten, C. J., Thomas, P. E., Guy, R. L., Lee, M., Gonzalez, F. J., Guengerich, F. P., and Yang, C. S., Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem. Res. Toxicol., 6, 511-518 (1993).
133. Penzak, S. R., Gubbins, P. O., Gurley, B. J., Wang, P. L., and Saccente, M., Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther. Drug Monitor., 21, 304-309 (1999).
134. Peter, R., Bocker, R., Beaune, P. H., Iwasaki, M., Guengerich, F. P., and Yang, C. S., Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 2E1. Chem. Res. Toxicol., 3, 566-573 (1990).
135. Peterson, L. A., Trevor, A., and Castagnoli, N. Jr., Stereochemical studies on the cytochrome P-450 catalyzed oxidation of (S)-nicotine to the (S)-nicotine delta 1′(5′)-iminium species. J. Med. Chem., 30, 249-254 (1987).
136. Petri, W. A. Jr., Chapter 48. Drugs used in the chemotherapy of tuberculosis, Mycobacteria avium complex disease, and leprosy, In Goodman & Gilman, The Pharmacological basis of therapeutics. Hardman, J. G., Limbird, L. L., and Gilman, A. G., (ed). 10th ed. Mc Graw-Hill, Medical Publishing Division, New York. P. 1275 (2001a).
137. Petri, W. A. Jr., Chapter 45. Penicillins, cephalosporins, and other b-lactam antibiotics, In Goodman & Gilman, The Pharmacological Basis of Therapeutics. Hardman, J. G., Limbird, L. L., and Gilman, A. G., (ed). 10th ed. Mc Graw-Hill, Medical Publishing Division, New York. P. 1197 (2001b).
138. Projean, D., Baune, B., Farinotti, R., Flinois, J. P., Beaune, P., Taburet, A. M., and Ducharme, J., In vitro metabolism of chloroquine: Identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab. Dispos., 31, 748-754 (2003).
139. Pussard, E., Barennes, H., Daouda, H., Clavier, F., Sani, A. M., Osse, M., Granic, G., and Verdier, F., Quinine disposition in globally malnourished children with cerebral malaria. Clin. Pharmacol. Ther., 65, 500-510 (1999).
140. Raghuram, T. C. and Krishnaswamy, K., Influence of nutritional status on plasma levels and relative bioavailability of tetracycline. Eur. J. Clin. Pharmacol., 12, 281-284 (1977).
141. Raghuram, T. C. and Krishnaswamy, K., Pharmacokinetics of tetracycline in nutritional edema. Chemotherapy, 28, 428-433 (1982).
142. Raghuram, T. C., Krishnaswamy, K., and Rao, K. V., Influence of dietary restriction and protein deficiency on plasma half-life and tissue distribution of tetracycline in rats. Clin. Exp. Pharmacol. Physiol., 9, 139-144 (1982).
143. Raj, N. S., Misra, A., Guleria, R., and Pande, J. N., Theophylline clearance in undernourished asthma patients. Indian J. Chest. Dis. Allied. Sci., 40, 175-178 (1998).
144. Raucy, J. L., Lasker, J. M., Lieber, C. S., and Black, M., Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch. Biochem. Biophys., 271, 270-283 (1989).
145. Rockich, K. and Blouin, R., Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats. Drug Metab. Dispos., 27, 1074-1077 (1999).
146. Rodvold, K. A., Clinical pharmacokinetics of clarithromycin. Clin. Pharmacokinet., 37, 385-398 (1999).
147. Roh, J. K., Rha, S. Y., Lee, C. I., Lee, K. H., Lee, J. J., Shim, H. J., Lee, S. D., Kim, W. B., Yang, J., Kim, S. H., and Lee, M. G., Phase I clinical trial: Pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study. Int. J. Clin. Pharmacol. Ther., 36, 312-319 (1998).
148. Ronis, M. J., Huang, J., Longo, V., Tindberg, N., Ingelman-Sundberg, M, and Badger, T. M. Expression and distribution of cytochrome P450 enzymes in male rat kidney: Effects of ethanol, acetone and dietary conditions. Biochem. Pharmacol., 55, 123-129 (1998).
149. Salako, L. A., Sowunmi, A., and Akinbami, F. O., Pharmacokinetics of quinine in African children suffering from kwashiorkor. Br. J. Clin. Pharmacol., 28, 197-201 (1989).
150. Sarich, T., Kalhorn, T., Magee, S., Al-Sayegh, F., Adams, S., Slattery, J., Goldstein, J., Nelson, S., and Wright, J., The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. Clin. Pharmacol. Ther., 62, 21-28 (1997).
151. Schuchmann, H. W., Rösch, W., Koch, U., Maurer, H. H., Stengl, U., and Sutschler, E., Pharmacokinetics of azosemide in patients with T-drain after cholecystectomy. Arzneim.-Forsch./Drug Res., 42, 812-814 (1992).
152. Seifart, H. I., Donald, P. R., de Villiers, J. N., Parkin, D. P., and Jaarsveld, P. P., Isoniazid elimination kinetics in children with protein-energy malnutrition treated for tuberculous meningitis with a four-component antimicrobial regimen. Ann. Trop. Paediatr., 15, 249-254 (1995).
153. Sharma, B., Mehta, S., Nain, C. K., and Mathur, V. S., Pharmacokinetic profile of antipyrine in young rhesus monkeys (Macaca mulatta) with protein energy malnutrition. Drug Nutr. Interact., 3, 93-98 (1985).
154. Sharma, B., Mehta, S., Nain, C. K., and Mathur, V. S., Disposition of chloramphenicol in young rhesus monkeys with protein-energy malnutrition. Drug Nutr. Interact., 4, 333-338 (1986).
155. Shim, H. J., Lee, E. D., Yoon, E. J., Lee, S. D., Kim, W. B., Yang, J., and Lee, M. G., Pharmacokinetics of FT-ADM after intravenous administration of DA-125, a prodrug of FT-ADM or FT-ADM to rats. A new adriamycin analog containing fluorine. Int. J. Pharm., 103, 147-154 (1994).
156. Siddoway, L. A., Roden, D. M., and Woosley, R. L., Clinical pharmacology of old and new antiarrhythmic drugs. Cardiovasc. Clin., 15, 199-248 (1985).
157. Smith, P. K., The pharmacology of salicylates and related compounds. Ann. N. Y. Acad. Sci., 86, 38-63 (1960).
158. Smith, D. E., Lin, E. T., and Benet, L. Z., Absorption and disposition of furosemide in healthy volunteers, measured with a metabolic-specific assay. Drug Metab. Dispos., 8, 337-342 (1980).
159. Sonne, J., Dragsted, J., Loft, S., Dossing, M., and Andreasen, F., Influence of a very low calorie diet on the clearance of oxazepam and antipyrine in man. Eur. J. Clin. Pharmacol., 36, 407-409 (1989).
160. Spatzenegger, M., Horsmans, Y., and Verbeeck, R. K., Differential activities of CYP1A isozymes in hepatic and intestinal microsomes of control and 3-methylcholanthrene-induced rats. Pharmacol. Toxicol., 86, 71-77 (2000).
161. Stafstrom, C. E., Nohria, V., Loganbill, H., Nahouraii, R., Boustany, R. M., and DeLong, G. R., Erythromycin-induced carbamazepine toxicity: A continuing problem. Arch. Pediatr. Adolesc. Med., 149, 99-101 (1995).
162. Suh, O. K., Kim, S. H., and Lee, M. G., Pharmacokinetics and pharmacodynamics of azosemide. Biopharm. Drug Dispos., 24, 275-297 (2003).
163. Syed, G. B., Sharma, D. B., and Raina, R. K., Pharmacokinetics of phenobarbitone in protein energy malnutrition. Dev. Pharmacol. Ther., 9, 317-322 (1986).
164. Szakacs, T., Veres, Z., and Vereczkey, L., Effect of phenobarbital and spironolactone treatment on the oxidative metabolism of antipyrine by rat liver microsomes. Pol. J. Pharmacol., 53, 11-19 (2001).
165. Tassaneeyakul, W., Mohamed, Z., Birkett, D. J., McManus, M. E., Veronese, M. E., Tukey, R. H., Quattrochi, L. C., Gonzalez, F. J., and Miners, J. O., Caffeine as a probe for human cytochromes P450: Validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics, 2, 173-183 (1992).
166. Tassaneeyakul, W., Birkett, D. J., McManus, M. E., Tassaneeyakul, W., Veronese, M. E., Andersson, T., Tukey, R. H., and Miners, J. O., Caffeine metabolism by human hepatic cytochromes P450: Contributions of 1A2, 2E1 and 3A isoforms. Biochem. Pharmacol., 47, 1767-1776 (1994).
167. Thummel, K. E., Lee, C. A., Kunze, K. L., Nelson, S. D., and Slattery, J. T., Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem. Pharmacol., 45, 1563-1569 (1993).
168. Tomkins, D. M., Otton, S. V., Joharchi, N., Li, N-Y., Balster, R. F., Tyndale, R. F., and Sellers, E. M., Effects of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J. Pharmacol. Exp. Ther., 280, 1374-1382 (1997).
169. Tomlinson, E. S., Lewis, D. F., Maggs, J. L., Kroemer, H. K., Park, B. K., and Back, D. J., In vitro metabolism of dexamethasone (DEX) in human liver and kidney: The involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modelling studies. Biochem. Pharmacol., 54, 605-611 (1997a).
170. Tomlinson, E. S., Maggs, J. L., Park, B. K., and Back, D. J., Dexamethasone metabolism in vitro: Species differences. J. Steroid. Biochem. Mol. Biol., 62, 345-352 (1997b).
171. Tranvouez, J. L., Lerebours, E., Chretien, P., Fouin-Fortunet, H., and Colin, R., Hepatic antipyrine metabolism in malnourished patients: Influence of the type of malnutrition and course after nutritional rehabilitation. Am. J. Clin. Nutr., 41, 1257-1264 (1985).
172. Treluyer, J. M., Sultan, E., Alexandre, J. A., Roux, A., Flouvat, B., and Lagardere, B., Pharmacokinetics of aspirin in African children with normal nutrition and malnutrition. Arch. Fr. Pediatr., 48, 337-341 (1991).
173. Treluyer, J. M., Roux, A., Mugnier, C., Flouvat, B., and Lagardere, B., Metabolism of quinine in children with global malnutrition. Metabolism of quinine in children with global malnutrition. Pediatr. Res., 40, 558-563 (1996).
174. Tsuchiya, K., Sasaki, S., and Marumo, F., Effect of azosemide on the in vitro perfused thick ascending limb of Henle's loop from the mouse. Pharmacology, 41, 195-199 (1990).
175. Tu, Y. Y., Peng, R., Chang, Z. F., and Yang, C. S., Induction of a high affinity nitrosamine demethylase in rat liver microsomes by acetone and isopropanol. Chem. Biol. Interact., 44, 247-260 (1983).
176. Tyndale, R. F., Li, Y., Li, N.-Y., Messina, E., Miksys, S., and Sellers, E. M., Characterization of cytochrome P-450 2D1 activity in rat brain: High-affinity kinetics for dextromethorphan. Drug Metab. Dispos., 27, 924-930 (1999).
177. Varma, D. R., Influence of dietary protein on the anti-inflammatory and ulcerogenic effects and on the pharmacokinetics of phenylbutazone in rats. J. Pharmacol. Exp. Ther., 211, 338-344 (1979).
178. Varma, D. R., Influence of dietary protein on the disposition and metabolism of phenylbutazone in rats. Can. J. Physiol. Pharmacol., 58, 231-236 (1980a).
179. Varma, D. R., Myocardial effects and pharmacokinetics of digoxin and ouabain in protein-deficient guinea pigs. Can. J. Physiol. Pharmacol., 58, 564-567 (1980b).
180. Varma, D. R. and Mulay, S., Anti-inflammatory and ulcerogenic effects and pharmacokinetics of dexamethasone in protein-deficient rats. J. Pharmacol. Exp. Ther., 214, 197-202 (1980).
181. Varma, D. R. and Yue, T. L., Influence of age, sex, pregnancy and protein-calorie malnutrition on the pharmacokinetics of salicylate in rats. Br. J. Pharmacol., 82, 241-248 (1984a).
182. Varma, D. R. and Yue, T. L., Influence of protein-calorie malnutrition on the pharmacokinetics, placental transfer and tissue localization of dexamethasone in rats. Br. J. Pharmacol., 83, 131-137 (1984b).
183. Wallace, R. J. Jr., Brown, B. A., Griffith, D. E., Girard, W., and Tanaka, K., Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J. Infect. Dis., 171, 747-750 (1995).
184. Wilson, R. C. and Green, N. K., Pharmacokinetics of minocycline hydrochloride in clinically normal and hypoproteinemic sheep. Am. J. Vet. Res., 47, 650-652 (1986).
185. Woodward, B. and Filteau, S. M., Immunoenhancement in wasting protein-energy malnutrition: Assessment of present information and proposal of a new concept. Adv. Nutr. Res., 8, 11-34 (1990).
186. Wrighton, S. A., Maurel, P., Schuetz, E. G., Watkins, P. B., Young, B., and Guzelian, P. S., Identification of the cytochrome P-450 induced by macrolide antibiotics in rat livers as the glucocorticoid responsive cytochrome P450p. Biochemistry, 24, 2171-2178 (1985).
187. Wykes, L. J., Fiorotto, M., Burrin, D. G., Rosario, M. D., Frazer, M. E., Pond, W. G., and Jahoor, F., Chronic low protein intakes reduce tissue protein synthesis in a pig model of protein malnutrition. J. Nutr., 126, 1481-1488 (1996).
188. Yoon, E. J., Lee, E. D., Yoon, W. H., Shim, H. J., Lee, S. D., Kim, W. B., Yang, J., and Lee, M. G., Pharmacokinetics, tissue distribution, and biliary excretion of FT-ADM after intravenous administration of DA-125, a prodrug of FT-ADM to dogs. New adriamycin analogues containing fluorine. Int. J. Pharm., 109, 181-187 (1994).
189. Yoon, E. J., Lee, W. I., Shim, H. J., Lee, S. D., Kim, W. B., Yang, J., and Lee, M. G., Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. Biopharm. Drug Dispos., 17, 373-420 (1996).
190. Yu, S. Y., Chung, H. C., Kim, E. J., Kim, S. H., Lee, I., Kim, S. G., and Lee, M. G., Efeects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: The role of CYP2E1 induction in 1,3-dimethyluric acid formation. J. Pharm. Pharmacol., 54, 1687-1692 (2002).
191. Yue, T. L. and Varma, D. R., Pharmacokinetics, metabolism, and disposition of salicylate in protein-deficient rats. Drug Metab. Dispos., 10, 147-152 (1982).
192. Zimmermann, T., Yeates, R. A., Albrecht, M., Laufun, H., and Wildfeuer, A., Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in Japanese. Int. J. Clin. Pharmacol. Res., 14, 87-93 (1994a).
193. Zimmermann, T., Yeates, R. A., Laufun, H., Pfaff, G., and Wildeuer, A., Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur. J. Clin. Pharmacol., 46, 147-150 (1994b).